Ben Towne Center for Childhood Cancer Research
Accelerating Progress Toward Cures
Dr. Julie Park is leading one of the world’s first clinical studies of immunotherapy for neuroblastoma – the deadliest childhood cancer.
You can help bring an end to childhood cancer all over the world, by supporting our Strong Against Cancer fundraising initiative.
Consolidative transplant after CAR T-cell therapy may benefit certain patients with acute lymphoblastic leukemia – 12.01.2018 – HemOnc Today
Consolidative hematopoietic stem cell transplant (HCST) after CD19-directed CAR T-cell therapy prolonged leukemia-free survival for certain pediatric and young adult patients with relapsed or refractory CD19-positive acute lymphoblastic leukemia, according to results of the PLAT-02 trial presented at ASH Annual Meeting and Exposition. However, investigators observed no significant difference in overall survival between patients who underwent consolidative HSCT and those who did not. This could be due to response to salvage therapy, according to researcher Dr. Corinne Summers, principal investigator in the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute. “Longer-term follow-up is needed, and I suspect that we may see a spread from those two lines eventually,” said Summers. “I’m happy that a lot of these patients who relapse after CAR T-cell therapy are salvageable with other therapies, but these are still very high-risk patients and we just need more time and more subjects under our belt.”
Researchers share key learnings from T-cell immunotherapy trials – 12.01.2018 – On the Pulse
Seattle Children’s recently enrolled its 200th immunotherapy patient, and now has nine CAR T-cell therapy trials targeting childhood cancers from leukemia to solid tumors. Seattle Children’s researchers are continuously discovering new best practices based on their experience in the trials, and as a result, shared six abstracts this weekend at the American Society of Hematology (ASH) Annual Meeting in San Diego. “It’s amazing to be at a place in our research where we’re learning from our existing trials, and immediately incorporating that vital intel into our new trials,” said Dr. Rebecca Gardner, oncologist and principal investigator for the PLAT-02 and PLAT-05 CAR T-cell immunotherapy trials. “We are also pleased to now offer several new trials to patients who would otherwise be out of treatment options. Our goal is to offer the best therapy possible, and to never let any patient reach the end of the line.” Key highlights include research on the potential benefit of bone marrow transplants by Dr. Corinne Summers, an oncologist and principal investigator in the Ben Towne Center for Childhood Cancer Research; research on boosting T cells from Dr. Colleen Annesley, an oncologist and principal investigator for the PLAT-03 trial; and Gardner’s research showing initial results from the PLAT-05 trial.
Collaborative aims to accelerate immunotherapy development for pediatric cancers – 10.12.2018 – HemOnc Today
Experts from several health systems have launched CureWorks, a collaborative effort to accelerate the development of immunotherapies for children with cancer. Participating institutions include Seattle Children’s, Children’s National Health System, BC Children’s Hospital and Children’s Hospital Los Angeles. Dr. Mike Jensen, executive director of CureWorks and director of Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute, said key components of the collaboration include the expansion of multisite clinical trials for immunotherapies developed by the academic partners, a centralized facility for reprogramming immune cells to recognize and fight cancer, and a network of member hospitals to share resources on the use of CAR T-cell therapy in pediatric populations. HemOnc Today spoke with Jensen about the need for immunotherapies for pediatric cancer populations, the advantages of collaboration and the goals of the initiative.